News und Analysen
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014: Purchase of own shares – final notice
EQS-News: Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures 2024: Net sales just below and earnings just above expectations – Forecast 2025
EQS-News: Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)
EQS-News: STRATEC TO PARTICIPATE IN THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2 High-Yield Dividend Stocks to Buy Early in 2025
The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb (NYSE: BMY) and Merck & Co. (NYSE: MRK) stand out for their
2 Reasons to Sell Merck Stock and 1 Reason to Buy
There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates
Is Merck the Next Big Weight-Loss Stock?
Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market.
Amidst an evolving field of competitors, the big pharma is committing
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks
Collecting dividend income on a recurring basis can help strengthen your financial position and be a way for you to be less dependent on other sources of cash flow. The one downside is that many
EQS-News: Expansion of the Management Board of M1 Kliniken AG
EQS-News: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
EQS-News: Reorganization of the Eckert & Ziegler Executive Board
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is
EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI
EQS-News: Eckert & Ziegler and SK Biopharmaceuticals Sign Actinium-225 Supply Agreement
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast
EQS-News: Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-News: NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary
EQS-News: FamiCord AG accelerates profitable growth in the third quarter of 2025 and further strengthens quality and visibility of revenues
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved HYRNUO® (sevabertinib), an oral, reversible, tyrosine kinase inhibitor (TKI), for the treatment of adult patients
EQS-News: MPH Health Care AG publishes figures for the third quarter of 2025: Equity (NAV) amounts to EUR 194.2 million, corresponding to EUR 45.36 per share. The equity ratio fell slightly to 92.8%